UCB says Cimzia shows 'significant' results in preventing damage to joints |
|
|
|
Published
:
Fri, 23 Feb 2007 08:27
|
BRUSSELS (AFX) - Pharmaceutical group UCB SA said its Cimzia treatment for rheumatoid arthritis, in combination with methotrexate, prevented structural damage of the joints to a significantly greater degree than placebo plus methotrexate after one's treatment.UCB said the results shown by radiographic data from a key phase three study of Cimzia were 'significant'.'(The study) achieved its co-primary endpoint, the inhibition of progression of structural damage,' said the group.'The study also showed that in both active treatment arms Cimzia improved the signs and symptoms of rheumatoid arthritis to a clinically statistically significantly greater degree than the placebo arm in patients who had inadequately responded to methotrexate alone,' it added.Similar results were observed with a second pivotal phase three study of Cimzia's subcutaneous liquid formulation.It said effective results in the treatment of the condition can be achieved with a 400mg total monthly dose of the drug.Further data from phase three studies will be presented at international rheumatology congresses later this year.Preparation for a licence submission in the treatment of rheumatoid arthritis is ongoing, with filing planned in the second half of 2007.simon.zekaria@thomson.comsz/cmrCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2792.28 |
22.57 (
0.81 %)
|
| SYMBOL (
2012-01-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
2017.00 |
46.00 (
2.42 %)
|
|
WHITBREAD
(
11:35am )
|
|
1662.99 |
33.99 (
2.09 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
IBM
(
12:34pm ) |
|
181.50 |
0.43 (
0.24 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
|
Print this Story
UCB confirms it will meet with FDA on Cimzia 